<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282447</url>
  </required_header>
  <id_info>
    <org_study_id>7376</org_study_id>
    <nct_id>NCT04282447</nct_id>
  </id_info>
  <brief_title>Screening of NASH in Oupatients Followed in Various Hospital Specialty Clinics at the University Hospital of Strasbourg</brief_title>
  <acronym>NASH-SPE</acronym>
  <official_title>Screening of NASH in Oupatients Followed in Various Hospital Specialty Clinics at the University Hospital of Strasbourg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to assess, by using a simple algorithm combining FIB-4 and&#xD;
      Fibroscan, the prevalence of NASH with advanced fibrosis in outpatients followed in various&#xD;
      hospital specialty clinics other than hepato/gastroenterology and to examine risk factors&#xD;
      associated with this condition. The prevalence of NASH will be investigated among 6 cohorts&#xD;
      of outpatients followed in different hospital specialty clinics at Hôpitaux Universitaires de&#xD;
      Strasbourg.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Actual">August 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated prevalence of NASH with advanced fibrosis among several hospital specialty clinics</measure>
    <time_frame>3 months</time_frame>
    <description>To assess the estimated prevalence of NASH , calcul of the FIB4</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients followed at specialty clinics in HUS and at risk of NAFLD: with at least one&#xD;
        metabolic risk factor (overweight, diabetes mellitus, hypertension, hypertriglyceridemia)&#xD;
        and/or elevated transaminases and/or liver steatosis on US.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  outpatients followed at specialty clinics in HUS and at risk of NAFLD: with at least&#xD;
             one metabolic risk factor (overweight, diabetes mellitus, hypertension,&#xD;
             hypertriglyceridemia) and/or elevated transaminases and/or liver steatosis on US.&#xD;
&#xD;
          -  endocrinology cohort : type 2 diabetes patients&#xD;
&#xD;
          -  infectious disease cohort : HIV positive patients&#xD;
&#xD;
          -  rheumatology cohort : patients with psoriasis, gout or rheumatoid arthritis&#xD;
&#xD;
          -  nephrology cohort : patients with chronic kidney disease such as diabetic nephropathy&#xD;
             or hypertensive nephropathy, including those receiving hemodialysis.&#xD;
&#xD;
          -  cardiology cohorts: patients with history of angina, myocardial infarction, stroke or&#xD;
             arteritis of lower limbs.&#xD;
&#xD;
          -  internal medicine cohort: patients with auto immune systemic diseases such as lupus,&#xD;
             sclerosis or rheumatoid arthritis.&#xD;
&#xD;
          -  subjects who have given their informed consent&#xD;
&#xD;
          -  Subjects affiliated to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  alcohol consumption &gt; 30g/d in male or &gt; 20g/d in female in the past 6 months&#xD;
&#xD;
          -  history of chronic viral hepatitis&#xD;
&#xD;
          -  history of liver auto immune disease, genetic hemochromatosis, Wilson disease&#xD;
&#xD;
          -  biliary disease, bile duct obstruction&#xD;
&#xD;
          -  drug-induced liver injury&#xD;
&#xD;
          -  secondary liver cancer or other active cancer&#xD;
&#xD;
          -  organ graft&#xD;
&#xD;
          -  use of medications associated with secondary NAFLD (corticosteroids, tamoxifen,&#xD;
             amiodarone, methotrexate).&#xD;
&#xD;
          -  congestive heart failure&#xD;
&#xD;
          -  AIDS&#xD;
&#xD;
          -  pregnancy, breastfeeding&#xD;
&#xD;
          -  no information could be given to the patient (subject faces emergency situation,&#xD;
             comprehension difficulties, etc.)&#xD;
&#xD;
          -  patient under guardianship&#xD;
&#xD;
          -  patients under judicial protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence SERFATY</last_name>
      <phone>+33 3 88 12 88 02</phone>
      <email>Lawrence.serfaty@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence SERFATY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille BESCH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gérald ROUL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques-Eric GOTTENBERG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel CHATELUS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David REY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno MOULIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence KESSLER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibault BAHOUGNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

